These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 22452349

  • 41. QSAR based therapeutic management of M. tuberculosis.
    Ahamad S, Rahman S, Khan FI, Dwivedi N, Ali S, Kim J, Imtaiyaz Hassan M.
    Arch Pharm Res; 2017 Jun; 40(6):676-694. PubMed ID: 28456911
    [Abstract] [Full Text] [Related]

  • 42. Genetics-directed drug discovery for combating Mycobacterium tuberculosis infection.
    Quan Y, Xiong L, Chen J, Zhang HY.
    J Biomol Struct Dyn; 2017 Feb; 35(3):616-621. PubMed ID: 26900080
    [Abstract] [Full Text] [Related]

  • 43. Virtual screening studies to identify novel inhibitors for Sigma F protein of Mycobacterium tuberculosis.
    Mustyala KK, Malkhed V, Chittireddy VR, Vuruputuri U.
    Int J Mycobacteriol; 2015 Dec; 4(4):330-6. PubMed ID: 26964817
    [Abstract] [Full Text] [Related]

  • 44. New tuberculostatic agents targeting nucleic acid biosynthesis: drug design using QSAR approaches.
    Bueno RV, Braga RC, Segretti ND, Ferreira EI, Trossini GH, Andrade CH.
    Curr Pharm Des; 2014 Dec; 20(27):4474-85. PubMed ID: 24245758
    [Abstract] [Full Text] [Related]

  • 45. Resisting resistant Mycobacterium tuberculosis naturally: mechanistic insights into the inhibition of the parasite's sole signal peptidase Leader peptidase B.
    Dhiman H, Dhanjal JK, Sharma S, Chacko S, Grover S, Grover A.
    Biochem Biophys Res Commun; 2013 Apr 19; 433(4):552-7. PubMed ID: 23510997
    [Abstract] [Full Text] [Related]

  • 46. Pyrrolidinone and pyrrolidine derivatives: Evaluation as inhibitors of InhA and Mycobacterium tuberculosis.
    Matviiuk T, Madacki J, Mori G, Orena BS, Menendez C, Kysil A, André-Barrès C, Rodriguez F, Korduláková J, Mallet-Ladeira S, Voitenko Z, Pasca MR, Lherbet C, Baltas M.
    Eur J Med Chem; 2016 Nov 10; 123():462-475. PubMed ID: 27490025
    [Abstract] [Full Text] [Related]

  • 47. Mycobacterium tuberculosis lysine-ɛ-aminotransferase a potential target in dormancy: Benzothiazole based inhibitors.
    Reshma RS, Jeankumar VU, Kapoor N, Saxena S, Bobesh KA, Vachaspathy AR, Kolattukudy PE, Sriram D.
    Bioorg Med Chem; 2017 May 15; 25(10):2761-2771. PubMed ID: 28389113
    [Abstract] [Full Text] [Related]

  • 48. When inhibitors do not inhibit: critical evaluation of rational drug design targeting chorismate mutase from Mycobacterium tuberculosis.
    Munack S, Leroux V, Roderer K, Ökvist M, van Eerde A, Gundersen LL, Krengel U, Kast P.
    Chem Biodivers; 2012 Nov 15; 9(11):2507-27. PubMed ID: 23161632
    [Abstract] [Full Text] [Related]

  • 49. Discovery of novel acetohydroxyacid synthase inhibitors as active agents against Mycobacterium tuberculosis by virtual screening and bioassay.
    Wang D, Zhu X, Cui C, Dong M, Jiang H, Li Z, Liu Z, Zhu W, Wang JG.
    J Chem Inf Model; 2013 Feb 25; 53(2):343-53. PubMed ID: 23316686
    [Abstract] [Full Text] [Related]

  • 50. Current Advances in Antitubercular Drug Discovery: Potent Prototypes and New Targets.
    Dos Santos Fernandes GF, Jornada DH, de Souza PC, Chin CM, Pavan FR, Dos Santos JL.
    Curr Med Chem; 2015 Feb 25; 22(27):3133-61. PubMed ID: 26282941
    [Abstract] [Full Text] [Related]

  • 51. Indole-2-carboxamide-based MmpL3 Inhibitors Show Exceptional Antitubercular Activity in an Animal Model of Tuberculosis Infection.
    Stec J, Onajole OK, Lun S, Guo H, Merenbloom B, Vistoli G, Bishai WR, Kozikowski AP.
    J Med Chem; 2016 Jul 14; 59(13):6232-47. PubMed ID: 27275668
    [Abstract] [Full Text] [Related]

  • 52. Fluoroquinolone derivatives and their anti-tubercular activities.
    Fan YL, Wu JB, Cheng XW, Zhang FZ, Feng LS.
    Eur J Med Chem; 2018 Feb 25; 146():554-563. PubMed ID: 29407980
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Design, Synthesis, and Evaluation of Novel Hybrid Efflux Pump Inhibitors for Use against Mycobacterium tuberculosis.
    Kumar M, Singh K, Naran K, Hamzabegovic F, Hoft DF, Warner DF, Ruminski P, Abate G, Chibale K.
    ACS Infect Dis; 2016 Oct 14; 2(10):714-725. PubMed ID: 27737555
    [Abstract] [Full Text] [Related]

  • 57. Opportunities for overcoming tuberculosis: Emerging targets and their inhibitors.
    Yang L, Hu X, Chai X, Ye Q, Pang J, Li D, Hou T.
    Drug Discov Today; 2022 Jan 14; 27(1):326-336. PubMed ID: 34537334
    [Abstract] [Full Text] [Related]

  • 58. In silico assessment of adverse effects of a large set of 6-fluoroquinolones obtained from a study of tuberculosis chemotherapy.
    Tusar M, Minovski N, Fjodorova N, Novic M.
    Curr Drug Saf; 2012 Sep 14; 7(4):313-20. PubMed ID: 23062244
    [Abstract] [Full Text] [Related]

  • 59. Structure-activity relationships on purine and 2,3-dihydropurine derivatives as antitubercular agents: a data mining approach.
    Pietra D, Imbriani M, Borghini A, Giorgi I, Settimo FD, Breschi MC, Campa M, Batoni G, Brancatisano FL, Bianucci AM.
    Chem Biol Drug Des; 2011 Oct 14; 78(4):718-24. PubMed ID: 21756283
    [Abstract] [Full Text] [Related]

  • 60. Small organic molecules targeting the energy metabolism of Mycobacterium tuberculosis.
    Urban M, Šlachtová V, Brulíková L.
    Eur J Med Chem; 2021 Feb 15; 212():113139. PubMed ID: 33422979
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.